SEC Form 4 · accession 0001209191-18-060707

TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Executive VP, Global R&D

Period of report

Nov 30, 2018

Accepted (ET)

Dec 4, 2018 · 8:09 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000818686

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Ordinary Shares^F1,F2	Nov 30, 2018	M	2,711	—	A	9,762	D
Ordinary Shares^F1,F4	Nov 30, 2018	S	933	$21.7621	D	8,829	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Share Units^F2,F5,F1	—	Nov 30, 2018	M	2,711	D	—	—	Ordinary Shares	2,711	8,133	D

F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.7600 to $21.7638, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019.